Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts speculate that Merck will buy out Astellas' U.S. vernakalant rights in a move that would be positive for Cardiome.